Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariana Chavez-MacGregor

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
JAMA Oncology|December 23, 2020
The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa-Maternal Orphans and a Cycle of DisadvantageMediget Teshome, Mariana Chavez-MacGregor
Breast (Edinburgh, Scotland)|February 24, 2024
Best of the year: Advanced breast cancer in 2023Ilana Schlam, Mariana Chavez-MacGregor
CA: a Cancer Journal for Clinicians|December 16, 2025
Bridging the cancer divide: Policy and structural solutions for equity in the United StatesMariana Chavez-MacGregor, Inimfon Jackson
The Lancet. Oncology|November 18, 2017
Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questionsMariana Chavez-MacGregor, Elizabeth A Mittendorf
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Randomized Clinical Trials and Observational Studies: Is There a Battle?Mariana Chavez-MacGregor, Sharon H Giordano
Annals of Surgical Oncology|August 18, 2017
All HER2-Positive Tumors are not Created EqualElizabeth A Mittendorf, Mariana Chavez-MacGregor
Clinical Advances in Hematology & Oncology : H&O|December 22, 2009
HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Expert Opinion on Investigational Drugs|September 22, 2012
Everolimus in the treatment of hormone receptor-positive breast cancerMariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Nature Reviews. Clinical Oncology|January 9, 2013
Breast cancer in 2012: New drugs, new knowledge, new targetsMariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Biomarkers in Medicine|February 11, 2016
Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?Misbat Chaudry, Jose Banchs, Mariana Chavez-MacGregor
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
JAMA Oncology|December 23, 2020
The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa-Maternal Orphans and a Cycle of DisadvantageMediget Teshome, Mariana Chavez-MacGregor
Breast (Edinburgh, Scotland)|February 24, 2024
Best of the year: Advanced breast cancer in 2023Ilana Schlam, Mariana Chavez-MacGregor
CA: a Cancer Journal for Clinicians|December 16, 2025
Bridging the cancer divide: Policy and structural solutions for equity in the United StatesMariana Chavez-MacGregor, Inimfon Jackson
The Lancet. Oncology|November 18, 2017
Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questionsMariana Chavez-MacGregor, Elizabeth A Mittendorf
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Randomized Clinical Trials and Observational Studies: Is There a Battle?Mariana Chavez-MacGregor, Sharon H Giordano
Annals of Surgical Oncology|August 18, 2017
All HER2-Positive Tumors are not Created EqualElizabeth A Mittendorf, Mariana Chavez-MacGregor
Clinical Advances in Hematology & Oncology : H&O|December 22, 2009
HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Expert Opinion on Investigational Drugs|September 22, 2012
Everolimus in the treatment of hormone receptor-positive breast cancerMariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Nature Reviews. Clinical Oncology|January 9, 2013
Breast cancer in 2012: New drugs, new knowledge, new targetsMariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Biomarkers in Medicine|February 11, 2016
Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?Misbat Chaudry, Jose Banchs, Mariana Chavez-MacGregor
Pageof 19